Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 09, 2016 8:53 PM ET

Pharmaceuticals

Company Overview of Tragara Pharmaceuticals, Inc.

Company Overview

Tragara Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the clinical and commercial development of drugs for the treatment of various cancers. The company was incorporated in 2005 and is based in Carlsbad, California.

3152 Lionshead Avenue

Suite 120

Carlsbad, CA 92010

United States

Founded in 2005

Phone:

760-208-6900

Fax:

760-208-6925

Key Executives for Tragara Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Co-Founder and Chief Operating Officer
Chief Financial Officer
Head of Oncology Biology
Head of Clinical Development
Age: 54
Compensation as of Fiscal Year 2015.

Tragara Pharmaceuticals, Inc. Key Developments

Tragara Pharmaceuticals and Lee's Pharma Sign Agreement to Develop and Commercialise Oncology Candidate TG02 in Asia

Tragara Pharmaceuticals (US) has agreed to license its oral multi-kinase inhibitor TG02 to Lee's Pharmaceutical (Hong Kong) affiliate China Oncology Focus. Under the agreement, Lee's Pharma receives exclusive rights to develop and commercialise TG02 in mainland China, Hong Kong, Macau, Taiwan, Brunei, Cambodia, East Timor, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam. In addition, Tragara receives cash payment, and potential future payments and royalties on future net sales. Lee's Pharma will finance the development, approval, and commercialisation of TG02 in its licensed territories, focusing initially on the clinical development of TG02 in the treatment of hepatocellular carcinoma (HCC).

Similar Private Companies By Industry

Company Name Region
Satiogen Pharmaceuticals, Inc. United States
Sanesco International Inc. United States
Tyler Distribution, Inc. United States
Ora, Inc. United States
ISW Group, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
August 28, 2015
--
Private Placement
July 15, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Tragara Pharmaceuticals, Inc., please visit www.tragarapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.